Related Experiment Videos
Randomised placebo-controlled study of atovaquone plus proguanil for malaria prophylaxis in children
Insights
Atovaquone plus proguanil is a highly effective antimalarial drug for preventing Plasmodium falciparum malaria in children. This combination demonstrated excellent safety and efficacy in a 12-week prophylaxis study.
Area of Science:
- Tropical Medicine
- Pharmacology
- Infectious Diseases
Background:
- Atovaquone and proguanil combination is effective for malaria treatment.
- Malaria prophylaxis requires safe and effective drug regimens.
Purpose of the Study:
- To assess the efficacy of atovaquone plus proguanil for malaria prophylaxis in children.
- To evaluate the safety profile of this drug combination during prophylaxis.
Main Methods:
- Randomized, double-blind, placebo-controlled trial involving 320 children in a hyperendemic area.
- Daily administration of atovaquone plus proguanil or placebo for 12 weeks after initial curative treatment.
- Monitoring of adverse events and weekly thick blood smears to detect malaria parasitemia.
Main Results:
- No Plasmodium falciparum malaria cases were observed in the atovaquone plus proguanil group (0/125).
- 25 malaria cases occurred in the placebo group (25/140), showing a statistically significant difference (p<0.001).
- Adverse events were similar between the treatment and placebo groups, indicating good tolerability.
Conclusions:
- Atovaquone plus proguanil is a highly effective and well-tolerated antimalarial for preventing Plasmodium falciparum malaria in children.
- This drug combination presents a viable alternative to current malaria prophylaxis regimens.
Background:
The combination of atovaquone and proguanil is highly effective and safe for the treatment of Plasmodium falciparum malaria. We aimed in this randomised, double-blind, placebo-controlled study to assess the efficacy and safety of this combination for malaria prophylaxis.
Methods:
320 children who lived in a hyperendemic area for P falciparum malaria were stratified by weight and randomly assigned atovaquone plus proguanil or placebo once daily for 12 weeks. All children received initial curative treatment with atovaquone and proguanil before the start of chemosuppression. We recorded adverse events daily and collected thick blood smears once a week. The primary endpoint was a positive blood smear.
Findings:
25 of 140 children in the placebo group and none of the 125 children in the atovaquone plus proguanil group had positive smears during chemosuppression (p<0.001). Adverse events during the chemosuppression phase did not differ between the groups.
Interpretation:
The combination of atovaquone plus proguanil is a highly effective and well-tolerated chemosuppressive antimalarial in children. This drug combination could replace current regimens.